
Workplace mistreatment impacts patient care
The UK’s General Optical Council (GOC) has published qualitative research into the effects of harassment, bullying, abuse and discrimination on optometrists and dispensing opticians. Carried out

The UK’s General Optical Council (GOC) has published qualitative research into the effects of harassment, bullying, abuse and discrimination on optometrists and dispensing opticians. Carried out

This season, Prodesign celebrates contrast, character and craft. “From bold expressions in acetate to the refined lines of titanium, every new model is designed with clarity of purpose and a confident point of view,” the Danish brand said. Signific, featured here, is a feminine and sophisticated lin

Kliik Denmark offers a wide repertoire of styling for narrow pupillary distance (PD) clientele with a strong sense of style, with its latest collection being where effortless style meets timeless design. The K-790, featured here, is the perfect frame for a man with a narrow PD wanting style and comf

Dutz’s latest collection is a bold fusion of expressive shapes, trendy palettes, tailor-made acetates and striking contrasts. For male fans of Dutz, model DZ2377-46 is the updated successor to Dutz bestseller DZ2309, now with a refined new twist. This squared men’s frame combines timeless Havana ace

LINK: https://www.nzoptics.co.nz/live-articles/valacyclovir-shows-promise-against-hzo/

Central serous chorioretinopathy (CSCR), characterised by serous detachment of the neurosensory retina and detachments of an altered retinal pigment epithelium (RPE), can be frustrating for both patie

VirtuaLens announced the launch of the Immersive IOL Simulator, described as a virtual reality (VR) platform to help cataract patients explore and compare intraocular lens (IOL) options before surgery

LINK: https://www.nzoptics.co.nz/live-articles/new-board-members-appointed/

An Israeli study found topical beta-blockers used to treat glaucoma were not associated with an increased risk of Parkinson’s disease (PD). Writing in the British Journal of Ophthalmology, autho

Ashvattha Therapeutics reported the results of a phase 2 trial of migaldendranib (MGB), its monthly ‘at-home’ subcutaneous anti-VEGF injection, showed it reduced treatment burden and improved visual a

LINK: https://www.nzoptics.co.nz/live-articles/optometry-s-salary-ceiling/

LINKS: https://nzoptics.co.nz/live-articles/save-sight-symposium-2024-ideas-and-innovations-in-eye-health/